Screener / SEC EDGAR /CIK 0000896622 /10-K filed Feb 6, 2026, compared with Feb 7, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Materials · Plastics Products

Aptargroup, Inc. ATR

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 6, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-11.4%

“The lower operating cash flow during 2025 was primarily a result of timing of payments on income taxes primarily in Germany, France and the US.”

Read it in the 10-K

Operating margin

Change, FY to Dec 31, 2025 vs Dec 31, 2024

13.9% to 13.3% (-0.6 pts)

The MD&A has no sentence that names a cause for this change.

Revenue

Change, FY to Dec 31, 2025 vs Dec 31, 2024

+5.4%

“Core sales to the consumer health care market declined 8% as higher demand for our eye care solutions was offset by lower sales of nasal decongestant, nasal saline and cough and cold products.”

Read it in the 10-K

“Core sales of our active material science solutions increased 3% as higher demand for our active film and diabetes treatment technologies more than compensated for lower tooling sales due to a large tooling sale in the previous year period.”

Read it in the 10-K

Net income

Change, FY to Dec 31, 2025 vs Dec 31, 2024

+4.9%

The MD&A has no sentence that names a cause for this change.

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +5.4%

    “Core sales to the consumer health care market declined 8% as higher demand for our eye care solutions was offset by lower sales of nasal decongestant, nasal saline and cough and cold products.”

    Read it in the FY 2025 10-K

    “Core sales of our active material science solutions increased 3% as higher demand for our active film and diabetes treatment technologies more than compensated for lower tooling sales due to a large tooling sale in the previous year period.”

    Read it in the FY 2025 10-K
  • FY 2024 +2.7%

    “Reported and core sales grew 3%, with annual sales of $3.6 billion, driven by favorable product mix and volume growth”

    Read it in the FY 2024 10-K

    “Core sales to the consumer health care market declined 4% as higher demand for our eye care solutions was offset by lower sales of nasal saline and cough and cold products due to a soft 2023-2024 cold and flu season and customer inventory management.”

    Read it in the FY 2024 10-K

Operating margin

0 of 2 years explained
  • FY 2025 -0.6 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +2.3 pts

    The FY 2024 MD&A has no sentence that names a cause for this change.

Net income

0 of 2 years explained
  • FY 2025 +4.9%

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +31.7%

    The FY 2024 MD&A has no sentence that names a cause for this change.

Cash from operations

2 of 2 years explained

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ATR/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.